Treatment of acute myocardial infarction with subcutaneous heparin at low doses.

Heparin has been used intensively in the treatment of acute myocardial infarction and preinfarction angina (PA) at full doses as a single drug by us. However, heparin may be used at smaller doses for similar purposes. These doses are not exactly anticoagulant, even though they reduce blood hypercoagulability, and act mainly in an antithrombotic capacity.

[Treatment of neurological forms of Argentinian hemorrhagic fever with cytarabine].

The effects of cytarabine on neurological forms of Argentina Hemorrhagic Fever were evaluated in 125 patients. The mortality was 12.88 per cent compared to 61.

[Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases].

During the 23 consecutive annual epidemics of Argentine haemorrhagic fever observed from 1959 to 1983, a group of 4,433 patients were treated at Junin (Argentina) with convalescent's plasma; the overall mortality rate was 3.29%. In 1958, before convalescent's plasma was used, the mortality rate in 448 patients who received the conventional treatment was 42.

Heparin effect on plasma fibrinogen in the thrombophilic syndrome.

The effects of heparin were studied in a group of 42 patients with preinfarction angina (PA) and acute myocardial infarction (AMI) whose plasma fibrinogen was increased. Plasma fibrinogen was measured by the turbidimetric method in timol turbidimetric units. Statistically significant results proved that heparin reduces the plasma fibrinogen progressively over a treatment period of 6 weeks.

[Medical treatment of the threat syndrome with heparin. Long-term prospective study].

A 19-year study of 119 patients stricken with a threat syndrome and treated with heparin is presented. The average observation period is 10.15 years.

Heparin effect on blood viscosity.

The effect of heparin on blood viscosity was investigated in a group of patients with acute myocardial infarction (AMI) and preinfarction angina (PA), whose blood viscosity was elevated. Viscosity was measured with Cannon, Fenske, and Routine viscometers. Kinematic viscosity, bath and whole blood, plasma, and serum viscosity were determined as well as dependent parameters (fibrinogen, serum proteins, number of platelets, and hematocrit).

Argentine hemorrhagic fever: early diagnosis by immunofluorescence.

A procedure that allows to ascertain a diagnosis of Argentine Hemorrhagic Fever (AHF) as early as 24-48 hours after onset of symptoms is described. An immunofluorescent (IF) test on round cells of urinary sediment was employed. The procedure was assayed on 31 patients with febrile syndrome during epidemic peaks of 1975-1976.

Immunogenicity of A/USSR (H1N1) subunit vaccine in unprimed young adults.

A clinical and serological study was performed on 267 of 636 volunteers vaccinated against Argentine hemorrhagic fever with the XJCl3 attenuated strain of Junin virus seven to nine years earlier, in order to determine their long-term evolution. This study included a clinical examination, a chest roentgenogram, an electrocardiogram, and the following laboratory determinations: white and red cell count, number of platelets, hematocrit, hemoglobin, sedimentation rate (Katz index), urea, nitrogen, glucose concentration, cholesterol, GOT, GPT, gamma GT, alkaline phosphatase, cholinesterase, and total bilirubin. Neutralization reactions were performed to determine presistence of antibody levels.